Amgen: EC Approves Prolia For Patients With Glucocorticoid-Induced Osteoporosis

Amgen Inc. (AMGN) said Friday that the European Commission or EC has approved a new indication for Prolia, or denosumab, for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.

from RTT - Biotech https://ift.tt/2Jq1LBX
via IFTTT